In part 4, Prof. Caplan talks about isolating mesenchymal stem cells from bone marrow using specialized; calf serum choosing different assays to prove multipotency – osteogenesis, chondrogenesis, adipogenesis; point of care with autologous bone marrow in orthopedic surgery; tissue engineering bone with lineage restricted MSCs; banking bone discarded bone marrow from orthopedic surgeries for future use;
June 18, 2013 by
VIDEO – The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 4)
June 11, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 3)
In part 3, Professor Caplan discusses the science behind mesenchymal stem cells: sources of mesenchymal stem cells (MSCs), because all MSCs are pericytes one can find them in any tissue that has blood vessels, pericytes express markers of MSCs, frequency of pericytes in human tissue, most abundant source of pericytes is adipose (fat) tissue, adipose-derived stem cells, how MSCs are separated from fat, chemistries MSCs from different tissues are not the same, MSCs function at sites of injury, mesenchymal stem cell homing in mice, MSCs don’t make fat, they don’t make muscle. They come back as pericytes, and not all pericytes are MSCs.
June 10, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 2)
In Part 2, Prof. Caplan discusses the two types of regenerative medicine: tissue engineering and in vivo tissue regeneration, hematapoietic and mesenchymal stem cells. All mesenchymal stem cells are pericytes and have immuno-modulatory and trophic properties
Prof. Caplan was speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia — Institute for Scientific Research and High Technology Services).
June 6, 2013 by
The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (VIDEO Part 1)
Professor Arnold Caplan of Case Western Reserve University is widely regarded as “The Father of the Mesenchymal Stem Cell”. This lecture is a “must see” for anyone interested in stem cell therapy. In Part 1, Prof. Caplan proposes a new regulatory pathway for approval of cell-based therapies and regenerative medicine called “Progressive Approval” to replace the current US FDA system that is now in place.
Prof. Caplan was speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia — Institute for Scientific Research and High Technology Services).
June 6, 2013 by
Arnold Caplan and Riccardo Calafiore inside Medistem Panama stem cell laboratory
Arnold Caplan PhD and Riccardo Calafiore
Prof. Arnold Caplan of Case Western Reserve University and Prof. Riccardo Calafiore of the University of Perugia, Italy inside our stem cell lab. Prof. Caplan and Prof. Calafiore toured one of our three clean rooms and viewed stem cells during their visit.
They were speaking in Panama City, Panama at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia – Institute for Scientific Research and High Technology Services).
May 20, 2013 by
Arnold Caplan PhD of Case Western Reserve University and Riccardo Calafiore of Perugia University in Italy tour Medistem stem cell lab in Panama
Arnold Caplan PhD, Neil Riordan PhD and Riccardo Calafiore MD at Medistem Labs Panama
Professor Arnold Caplan (left) and Professor Riccardo Calafiore (right) pose with Medistem Labs Panama Founder, Neil Riordan, PhD. Dr. Riordan is also the Founder of Stem Cell Institute in Panama City, Panama.
Prof. Caplan and Prof. Calafiore were in Panama City with Amit Patel MD to speak at “La Medicina Del Futuro En El Presente”, an event organized by the honarable Ruben Berrocal MD, Minister of Science, Technology and Innovation SENACYT (National Secretariat of Science, Technology and Innovation) and Prof. K. S. Jagannatha Rao, Ph.D., FNASc, FABAP, FASB, FLS (Reino Unido) Director INDICASAT-AIP (Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia – Institute for Scientific Research and High Technology Services).
Prof. Caplan is a Professor of Biology and General Medical Sciences (oncology) at Case Western Reserve University and the Director of the Skeletal Research Center at Case Western Reserve. Prof. Caplan is widely regarded as “The father of the mesenchymal stem cell”.
Prof. Calafiore is the Head of the Division of Endocrinology and Metabolism at the Medical School at the University of Perugia, Italy and Director of the Interdisciplinary Laboratory for Endocrine and Organ Transplant at the University of Perugia School of Medicine. He is also a director at ALTuCELL.
Amit Patel, MD, MS, is an associate professor in the Division of Cardiothoracic Surgery at the University of Utah School of Medicine and Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah
Neil Riordan PhD is Founder of Stem Cell Institute in Panama City, Panama and the President of Medistem Panama. He is also CEO of Aidan Products.
April 30, 2013 by
The dual effect of MSCs on tumour growth and tumour angiogenesis
Michelle Kéramidas, Florence de Fraipont, Anastassia Karageorgis, Anaïck Moisan, Virginie Persoons, Marie-Jeanne Richard, Jean-Luc Coll and Claire Rome
Abstract (provisional)
Introduction
Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Methods
In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.
Results
Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.
Conclusions
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Original Link: http://stemcellres.com/content/4/2/41/abstract
March 13, 2013 by
Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients
Cell Transplant. 2013 Feb 26. [Epub ahead of print]
El-Kheir WA, Gabr H, Awad MR, Ghannam O, Barakat Y, Farghali HA, Maadawi ZM, Ewes I, Sabaawy HE.
Abstract
Spinal cord injuries (SCI) cause sensory loss and motor paralysis and are treated with physical therapy, but most patients fail to recover due to limited neural regeneration. Here we describe a strategy in which treatment with autologous adherent bone marrow cells is combined with physical therapy to improve motor and sensory functions in early-stage chronic SCI patients
In a phase I/II controlled single-blind clinical trial (clinicaltrials.gov identifier: NCT00816803), 70 chronic cervical and thoracic SCI patients with injury durations of at least 6 months were treated with either intrathecal injection(s) of autologous adherent bone marrow cells combined with physical therapy, or with physical therapy alone. Patients were evaluated with clinical examinations, electrophysiological somatosensory evoked potential, MRI imaging, and functional independence measurements.
Chronic cervical and thoracic SCI patients treated with autologous adherent bone marrow cells combined with physical therapy showed functional improvements over patients in the control group treated with physical therapy alone, and there were no cell therapy-related side effects. At 18 months posttreatment, 23 of the 50 cell therapy-treated cases (46 percent) showed sustained improvement using the American Spinal Injury Association (ASIA) Impairment Scale (AIS). Compared to those patients with cervical injuries, a higher rate of functional improvement was achieved in thoracic SCI patients with shorter durations of injury and smaller cord lesions.
Therefore, when combined with physical therapy, autologous adherent bone marrow cell therapy appears to be a safe and promising therapy for patients with chronic spinal cord injuries. Randomized controlled multicenter trials are warranted.
March 12, 2013 by
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic
Leo Bockeria, Vladimir Bogin, Olga Bockeria, Tatyana Le, Bagrat Alekyan, Erik J Woods, Amalia A Brown, Thomas E Ichim and Amit N Patel
Journal of Translational Medicine 2013, 11:56 doi:10.1186/1479-5876-11-56
Published: 5 March 2013
Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in the heart have made stem cell therapeutics the Holy Grail of modern cardiovascular medicine. The success of cardiac regenerative therapies hinges on the combination of an effective allogeneic “off the shelf” cell product with a practical delivery system. In 2007 Medistem discovered the Endometrial Regenerative Cell (ERC), a new mesenchymal-like stem cell. Medistem and subsequently independent groups have demonstrated that ERC are superior to bone marrow mesenchymal stem cells (MSC), the most widely used stem cell source in development. ERC possess robust expansion capability (one donor can generate 20,000 patients doses), key growth factor production and high levels of angiogenic activity. ERC have been published in the peer reviewed literature to be significantly more effect at treating animal models of heart failure (Hida et al. Stem Cells 2008).Current methods of delivering stem cells into the heart suffer several limitations in addition to poor delivery efficiency. Surgical methods are highly invasive, and the classical catheter based techniques are limited by need for sophisticated cardiac mapping systems and risk of myocardial perforation. Medistem together with Dr. Amit Patel Director of Clinical Regenerative Medicine at University of Utah have developed a novel minimally invasive delivery method that has been demonstrated safe and effective for delivery of stem cells (Tuma et al. J Transl Med 2012). Medistem is evaluating the combination of ERC, together with our retrograde delivery procedure in a 60 heart failure patient, double blind, placebo controlled phase II trial. To date 17 patients have been dosed and preliminary analysis by the Data Safety Monitoring Board has allowed for trial continuation.The combined use of a novel “off the shelf” cell together with a minimally invasive 30 minute delivery method provides a potentially paradigm-shifting approach to cardiac regenerative therapy.
http://www.translational-medicine.com/content/11/1/56/abstract
February 18, 2013 by
MS Radio – Stem cells can change our lives
On Tuesday, February 19th, 2013
at 5pm EST
Stem Cells Change Lives
Click here to Listen Online
or Call (347) 327-9317
Toll Free (877) 497-9936
Join us on Multiple Sclerosis Radio as the Director of MSstation™ Radio Judi Lecoq and her panel of nine individuals candidly share their testimonies of living with Multiple Sclerosis and their experiences after undergoing Stem Cell Treatment.
Judi Lecoq
I was diagnosed with Secondary Progressive Multiple Sclerosis in 1997, and began the Stem Cell Journey, with Fundraising January 2010.
SammyJo Wilkinson
Diagnosed ’95 relapsing remitting MS, secondary progressed by 2002. May 2012 I had adult stem cells in Houston, TX
Jennifer Ziegler
I was diagnosed with MS in 2004. I started thinking about Adult Stem Cell Therapy around 6 yrs. ago.
Holly Huber
Diagnosed with Multiple Sclerosis in 2004. Within months of my official diagnosis, I couldn’t walk. I was quickly facing having to live the rest of my life in a wheelchair and needing to depend on someone else 24/7 for survival. After 9 months of clinical research, in 2008 I had my first stem cell treatment.
Fiona Sparrow
Diagnosed 2005 with RRMS in 2009. Then I was told I had Malignant MS an extremely aggressive form. Only 3-5% of patients have this form. In December 29/2011 I underwent a full bone marrow transplant/stem cell transplant!
Annette Williams
Diagnosed with Relapsing Remitting MS in 2008. In 2010 it progressed to secondary progressive. I heard about stem cell therapy and begin researching about it. Following a fund raiser I went and had adult stem cells.
Carla Hickman
Diagnosed in May of 2003 with Relapsing Remitting Multiple Sclerosis. I began looking into stem cells in 2009 and went to Costa Rica in 2010.
Kane Roper
Diagnosed with Multiple Sclerosis for roughly 7 – 8 years, before receiving stem cell treatment last Christmas.
Richard Humphries
In October of 2005 after several hundred tonic seizures, I was diagnosed with Relapsing Remitting Multiple Sclerosis. By March 2007, it transition to Secondary Progressive MS. My wife and I were looking at a wheelchair. By the time I chose to have his first Stem Cell Treatments in 2008, I was completely bedridden. My Stem Cell Journey is long and varied.
Preston Walker
Diagnosed on Dec. 2001 with RRMS. I went down for ASC treatment on May 2008, June of 2009 and July of 2010.
